RNA — Avidity Biosciences Share News
0.000.00%
Last trade - 00:00- $11.27bn
- $9.40bn
- $10.90m
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Brief: Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (updated)
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026
Sarepta rises after U.S. FDA clears study of muscle-wasting disease drug
Brief: Avidity Biosciences Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44
Avidity Biosciences reports wider-than-expected Q3 net loss
U.S. RESEARCH ROUNDUP-ATI, GoDaddy, Lyft
U.S. RESEARCH ROUNDUP- BCB Bancorp, Cadence Design Systems, Intellia Therapeutics
Novartis Q3 operating income up 6% on new drug sales (updated)
Novartis Q3 operating income up 6% on new drug sales
Deals of the day-Mergers and acquisitions
Novartis CEO defends $12 billion deal for Avidity as 'appropriate risk to take' (updated)
U.S. STOCKS ON THE MOVE-PepGen, Turbo Energy, Qualcomm
PepGen, Dyne rise after Novartis' $12 bln deal to buy rival Avidity
Avidity Biosciences hits record high after Novartis' $12 bln deal to buy co